ADHD and EEG-neurofeedback: a double-blind randomized placebo-controlled feasibility study by Lansbergen, M. M. et al.
BIOLOGICAL CHILD AND ADOLESCENT PSYCHIATRY - ORIGINAL ARTICLE
ADHD and EEG-neurofeedback: a double-blind randomized
placebo-controlled feasibility study
M. M. Lansbergen • M. van Dongen-Boomsma •
J. K. Buitelaar • D. Slaats-Willemse
Received: 20 July 2010/Accepted: 31 October 2010/Published online: 17 December 2010
 The Author(s) 2010. This article is published with open access at Springerlink.com
Abstract Electroencephalography (EEG)-neurofeedback
has been shown to offer therapeutic beneﬁts to patients
with attention-deﬁcit/hyperactivity disorder (ADHD) in
several, mostly uncontrolled studies. This pilot study is
designed to test the feasibility and safety of using a double-
blind placebo feedback-controlled design and to explore
the initial efﬁcacy of individualized EEG-neurofeedback
training in children with ADHD. Fourteen children
(8–15 years) with ADHD deﬁned according to the
DSM-IV-TR criteria were randomly allocated to 30 ses-
sions of EEG-neurofeedback (n = 8) or placebo feedback
(n = 6). Safety measures (adverse events and sleep prob-
lems), ADHD symptoms and global improvement were
monitored. With respect to feasibility, all children com-
pleted the study and attended all study visits and training
sessions. No signiﬁcant adverse effects or sleep problems
were reported. Regarding the expectancy, 75% of children
and their parent(s) in the active neurofeedback group and
50% of children and their parent(s) in the placebo feedback
group thought they received placebo feedback training.
Analyses revealed signiﬁcant improvements of ADHD
symptoms over time, but changes were similar for both
groups. This pilot study shows that it is feasible to conduct
a rigorous placebo-controlled trial to investigate the efﬁ-
cacy of neurofeedback training in children with ADHD.
However, a double-blind design may not be feasible since
using automatic adjusted reward thresholds may not work
as effective as manually adjusted reward thresholds.
Additionally, implementation of active learning strategies
may be an important factor for the efﬁcacy of EEG-
neurofeedback training. Based on the results of this pilot
study, changes are made in the design of the ongoing study.
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Introduction
Attention-deﬁcit/hyperactivitydisorder(ADHD)isthemost
common psychiatric disorder in childhood, affecting about
5% of all children worldwide (Polanczyk et al. 2007). In
40–60% of all cases ADHD persists in adolescence and
adulthood, leading to a variety of problems such as poor
academic performance, poor socialization, and increased
trafﬁc accidents (Faraone et al. 2006). Primary treatment for
ADHD is medication, particularly psychostimulants. How-
ever, around 20% of all children with ADHD fail to respond
to psychostimulants (Swanson et al. 1998) and in many
responders there is still room for improvement. Moreover,
minor and serious adverse side effects have been reported
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appetite (Charach et al. 2004, 2006). Long-term follow-up
evaluation (22 months after the treatment period) has also
indicated that a substantial part of the ADHD children that
startedmedication at7–9 yearsstoppedwithin2 years,after
whichclinicalsymptomsofADHDreappeared(Jensenetal.
2007; Murray et al. 2008).
Electroencephalography (EEG)-neurofeedback appears
to be a promising alternative or additional treatment without
reported adverse effects (Arns et al. 2009; Gevensleben
et al. 2009; Heinrich et al. 2007; Monastra et al. 2005).
EEG-neurofeedback training involves the self-regulation of
ongoing neuronal oscillations (recorded by EEG) in one or
morefrequencybands byvisual orauditoryfeedback, aimed
at normalizing and/or self-regulating brain activity. Chan-
ges made in the desired direction are rewarded, for example
positively reinforced by presenting generally pleasant tones
or pictures. Given the increased slow frequency oscillations
(theta) and decreased high frequency oscillations (beta) in
ADHD patients (Barry et al. 2003), one of the most often
used and investigated EEG-neurofeedback training in
ADHD involves increasing the production of beta activity
(16–20 Hz) while suppressing the production of theta
activity (4–8 Hz). The goal is to reduce symptoms of
ADHDandto improve cognitive (and daily life) functioning
(Gevensleben et al. 2009; Heinrich et al. 2007; Monastra
et al. 2005). A different, frequently used EEG-neurofeed-
back training in ADHD involves suppressing of theta
activity and simultaneously increasing sensorimotor rhythm
(SMR; 12–15 Hz; Monastra et al. 2005). Neurofeedback
training of slow cortical potentials (SCP) has also been
conducted (Doehnert et al. 2008; Gevensleben et al. 2009),
aimed at learning to regulate phasic (rather than tonic)
cortical excitability. In SCP neurofeedback training, the
task is to generate alternately negative and positive SCPs.
Seven controlled trials have assessed the efﬁcacy of
neurofeedback training (EEG and SCP) in children with
ADHD, and demonstrated improvement of ADHD symp-
toms and cognitive functions (i.e., enhanced attention and
inhibition) after neurofeedback training compared to a
control condition (Drechsler et al. 2007; Gevensleben et al.
2009; Heinrich et al. 2004; Levesque et al. 2006) and
similar improvements compared to psychostimulants
(Fuchs et al. 2003; Monastra et al. 2002; Rossiter 2004).
Moreover, recently a 6 months follow-up study provided
evidence for long-term beneﬁts of neurofeedback training
in children with ADHD (Gevensleben et al. 2010). Changes
in trained EEG oscillations after EEG-neurofeedback
training are less straightforward and only demonstrated in
two ADHD studies (Gevensleben et al. 2010; Monastra
et al. 2002). Ambiguous changes in resting-state EEG
activity after EEG-neurofeedback training have also been
reported for other populations (e.g., Fernandez et al. 2007
in learning disabled children; Vernon 2005 in healthy
volunteers), suggesting a reorganization of EEG activity
rather than local changes in activity at trained electrode
sites (Fernandez et al. 2007). A recent meta-analysis on the
clinical effects of neurofeedback in ADHD reported large
effect sizes for inattention and impulsivity and medium
effects sizes for hyperactivity (Arns et al. 2009).
Although positive results after EEG-neurofeedback
training in ADHD have been reported in seven controlled
studies, it should be noted that the majority of studies had
serious methodological problems. The most important
methodological limitations of previous studies were small
sample size, non-randomized group assignment, and con-
trol conditions that do not control for unspeciﬁc effects
since they lack a double-blind setup (Heinrich et al. 2007).
Before EEG-neurofeedback treatment can be recom-
mended as a standard treatment for ADHD and can be
incorporated in current guidelines for ADHD, the results
should be replicated and extended in more rigorous and
scientiﬁcallycontrolleddesigns.Onlyinthreestudies,group
assignment was randomized (Gevensleben et al. 2009;
Heinrich et al. 2004; Levesque et al. 2006). The imple-
mentation of a control condition for EEG-neurofeedback is
difﬁcult: on the one hand it should be non-speciﬁc; on the
other hand it should meet ethical standards (La Vaque and
Rossiter 2001). Control conditions that have been used are a
waiting list control group (Heinrich et al. 2004; Levesque
et al. 2006), group therapy (Drechsler et al. 2007), and a
computerized attention training (Gevensleben et al. 2009).
Althoughgrouptherapy and computerizedattentiontraining
control for unspeciﬁc effects such as invested time and
attentionandtreatmentexpectancies,fromamethodological
point of view the best control condition would be a placebo-
neurofeedback condition in which provided feedback is
similar to neurofeedback, but not related to the child’s own
brain activity. The unspeciﬁc factors in this placebo-feed-
backconditionareequaltotheunspeciﬁcfactorsinanactive
EEG-neurofeedback training (e.g., Fernandez et al. 2007 in
learning disabled children; Egner et al. 2002 in healthy
volunteers; Angelakis et al. 2007 in elderly people; Loge-
mann et al. 2010 in healthy volunteers). An important
advantage of implementing placebo-feedback training is
that it allows children and parents
1 who participate in the
study as well as researchers and trainers involved in
the study to be blind for group allocation. This minimizes
the effects of unspeciﬁc factors. However, implementing a
placebo control condition in a randomized controlled trial
may lead to ethical concerns when effective standard
1 In the study from Gevensleben et al. (2009) parents were not
informed about the treatment their child received and were not
allowed into the room in which the intervention was given, but at the
end of the training period approximately 60% of all parents could
reliably indicate which training their child received.
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123treatments like medication are available (La Vaque and
Rossiter 2001). Moreover, it has been argued that placebo-
neurofeedback training is not feasible since it is clearly
recognized by the patient (Kotchoubey et al. 2001).
In addition to a placebo-controlled design, it is impor-
tant to monitor adverse events such as headaches and sleep
problems, structurally during the training period to test the
safety of (placebo)-neurofeedback training. None of the
previous studies monitored potential adverse events.
So far, neurofeedback studies in ADHD children have
used standardized neurofeedback training (mostly theta
suppression/beta enhancement). Based on the observations
that(1)notallchildrenwithADHDhaveincreasedthetaand
decreased beta activity (Arns et al. 2008; Clarke et al. 2001;
Van Dongen-Boomsma et al. 2010) and (2) increased theta
inADHDmay partly bedue toslow alpha oscillationsrather
than real enhanced theta activity (Lansbergen et al. 2010),
EEG-neurofeedback training may be more effective when
adjusted to the child’s brain activity (i.e., individualized
EEG-neurofeedback training). Indeed, this approach of
individualized EEG-neurofeedback training is widely
applied in clinical practice. The question remains whether
individualized EEG-neurofeedback training as applied in
clinical practice, may also be effective in improving symp-
toms of ADHD when applied in a scientiﬁc study design.
To summarize, EEG-neurofeedback training appears to
be a promising treatment for ADHD, although a placebo-
controlled double-blind trial including safety measures is
needed to provide concluding evidence for the efﬁcacy and
safety of EEG-neurofeedback training in ADHD. More-
over, evidence for the efﬁcacy of individualized EEG-
neurofeedback training (mostly applied in clinical practice)
is lacking. In the present pilot study, the main objective is
to test the feasibility and safety of using a rigorous double-
blind placebo feedback-controlled design in studying the
effects of individualized neurofeedback training in children
with ADHD. In order to provide a double-blind interven-
tion, placebo/sham feedback was implemented which was
equal to the EEG-neurofeedback training except that
feedback was based on a simulated EEG signal instead of
real brain activity (for similar approach, see Logemann
et al. 2010). To meet the ethical standards, all participating
children were allowed to continue their medication for
ADHD, if any, and provided that there was enough room
for further symptomatic improvement (see ‘‘Methods’’).
Methods
Participants
Children with ADHD (8–15 years) were recruited among
referrals from Karakter University Centre for Child and
Adolescent Psychiatry Nijmegen and from parents who
responded to advertisements. Children were included if (1)
they had been diagnosed with ADHD as classiﬁed by the
DSM-IV-TR (APA 2000), (2) they had an estimated IQ of at
least 80, (3) their QEEG deviated at least 1.5 standard
deviation (SD) from a normative database (see ‘‘EEG-
neurofeedback training and placebo feedback training’’),
and (4) they were psychopharmaca- naı ¨ve or -free, or used a
stable dosage of psychostimulants or atomoxetine with
room for improvement. Room for improvement was deﬁned
as an average score of more than 1 SD above the mean on
ADHD-DSM-IV rating scale (DuPaul et al. 1998). Children
on a stable dosage of psychostimulants or atomoxetine were
included in this study for several reasons. First, since the
majority of ADHD children use medication, excluding them
would preclude generalization of the results. Second, dis-
continuation of psychostimulants or atomoxetine in ADHD
would be withholding an evidence-based and recommended
treatment. Third, recent ﬁndings indicate that EEG-neuro-
feedback training should be embedded in a multimodal
treatment program (Gevensleben et al. 2009).
Children were excluded if they (1) were involved in
intensive (i.e., weekly) individual or group psychotherapy
during the experiment, (2) used medication other than
psycho-stimulants or atomoxetine, (3) had a comorbid
disorder, other than oppositional deﬁant disorder (ODD) or
an anxiety disorder, (4) had a neurological disorder and/or
a cardiovascular disease, (5) participated in another clinical
trial, (5) received neurofeedback training in the past, or (5)
used alcohol or drugs.
So far (recruitment period: Sept 2008–April 2009), 26
parents and children (when older than 12 years of age) gave
their written informed consent. Twelve children with
ADHD had to be excluded from participation for the fol-
lowing reasons: 2 children did not show enough room for
improvement, 2 children had an IQ below 80, 2 children did
not have clear deviations in their EEG, 1 child had
comorbid Gilles de la Tourette, 4 children did not have
ADHD as main diagnosis and 1 child did not show up at the
baseline measurements. Finally, 14 children with ADHD
(mean age 10.2 ± 2.0 years; 1 girl) completed the study
and were pseudo randomly double-blind allocated to one of
the two groups. Eight children were assigned to the EEG-
neurofeedback training (10.4 ± 2.3 years) and 6 children to
the placebo feedback training (10.0 ± 1.7 years; 1 girl).
The study was approved by the Dutch Central Medical
Ethics Committee (http://www.ccmo.nl) and conducted in
accordance with the declaration of Helsinki. All parents
and children older than 12 years of age gave their written
informed consent before participation, children younger
than 12 year gave their oral consent. Participation was
rewarded by a present for the children. Travel expenses
were partially reimbursed.
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First, all children were screened in a telephone interview
with their parents addressing past and current ADHD
symptoms; psychiatric and medical disorders, use of
medication, intelligence level, and autistic traits (Social
Communication Questionnaire, SCQ; Berument et al.
1999). A positive screening was followed by an extensive
diagnostic procedure, including developmental interview,
child psychiatric interview, and information by parents and
teachers using scores on the Achenbach scales (CBCL and
TRF), supervised by a child and adolescent psychiatrist.
The diagnosis had to be conﬁrmed by clinical scores on the
ADHD-DSM-IV rating scale by the investigator (DuPaul
et al. 1998). The presence of comorbid disorders was
established in the child psychiatric interview and by using
the Dutch electronic version of the Diagnostic Interview
Schedule for Children (DISC-DSM-IV, parent version;
Shaffer et al. 2000; Steenhuis et al. 2009). General func-
tioning and severity of clinical symptoms were assessed
using the Children’s Global Assessment Scale (CGAS;
Shaffer et al. 1983) and the Clinical Global Impression-
Severity Scale (CGI-S; Bangs et al. 2008), respectively. If
children’s IQ was not assessed within the past 1.5 years,
two subtests of the Wechsler Intelligence Scale for Chil-
dren (WISC-III) were administered (i.e., Vocabulary and
Block Design), to estimate intelligence. Validity coefﬁ-
cients for the Vocabulary and Block Design scores relative
to the full form are 0.88 for verbal IQ and 0.83 for per-
formance IQ (Antshel et al. 2007). Finally, a 20-min
electroencephalogram (EEG) was recorded to assess whe-
ther children’s QEEG deviated from the normative data-
base (see ‘‘EEG-neurofeedback training and placebo
feedback training’’).
Study design
A stratiﬁed, randomized, double-blind, sham-controlled
between-subjects design was utilized. Children with
ADHD were stratiﬁed according to age (i.e., younger vs.
older than 12 years), use of medication (with vs. without
medication), and EEG subtype (i.e., characterized by
increased slow oscillations or by increased fast oscillations,
as assessed by visual inspection of the raw EEG data), and
subsequently randomly double-blind allocated to one of the
following two groups: (1) EEG-neurofeedback and (2)
placebo feedback.
All participating children, their parents, and all people
involved in the study were blind to group assignment,
except for the principal investigator who was not involved
in data-collection, data-entry and data-analysis (J.K.
Buitelaar).
EEG-neurofeedback training and placebo feedback
training
Neurofeedback Instituut Nederland B.V. (NIN) provided
EEG-neurofeedback training and placebo feedback train-
ing. To account for electrophysiological heterogeneity,
individualized neurofeedback protocols were used for
EEG-neurofeedback training. Individualized neurofeed-
back protocols were determined by NIN based on visual
inspection of children’s EEG recorded before training and
based on the comparison of the quantitative EEG (QEEG)
with the NeuroGuide database (http://www.applied
neuroscience.com; Thatcher 1998) (Table 1, see also
‘‘Electrophysiological recordings’’). The NeuroGuide
database contains EEG data from 625 healthy individuals
(58.9% males) of which 470 are children between 1 and
15 years old. For all subjects in the database, EEG data was
recorded from 19 electrodes placed according to the 10–20
electrode international system and referenced to linked ear
lobes during an eyes closed and eyes open resting-state
condition (Thatcher 1998).
For all children in the present study, eyes open and eyes
closed raw EEG data were visually inspected and quanti-
tative EEG (QEEG) data from each participant before
EEG-neurofeedback training was analyzed using Deymed
Truescan software. EEG data with eye movements and
artifacts were removed. Subsequently, individual QEEGs
were compared to the NeuroGuide database and deviations
from the normative database were identiﬁed (FFT maximal
z scores). The aim of the EEG-neurofeedback training was
to normalize power within speciﬁc frequency bands and
at speciﬁc electrode sites (for the same procedure, see
Logemann et al. 2010). As shown in Table 1, most
participants were learned to increase the production of
sensorimotor rhythm (SMR) while simultaneously sup-
pressing the production of theta activity.
BrainMaster Atlantis hardware and software was used to
provide EEG-neurofeedback training and placebo-feedback
training. Identical procedures were provided to the children
Table 1 Individualized EEG-neurofeedback training protocols
Child Site Theta stop
(Hz)
SMR go
(Hz)
High stop
(Hz)
997 F3 and F4 4–7 12–15 20–30
999 F3 and F4 4–7 12–15 20–30
995 C3 and C4 4–7 12–15
992 P3 and C4 4–6 12–15
989 P3 and P4 4–7 12–15
987 Fz 4–7 12–15
984 C3 and C4 4–7 12–15
983 C3 and C4 15–20 ? 20–25
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123in the EEG-neurofeedback group and placebo feedback
group, except that children in the EEG-neurofeedback
group received feedback on their real-time EEG-signal,
whereas children in the placebo feedback group received
feedback on a simulated EEG signal, generated by Brain-
Master Atlantis software (Logemann et al. 2010). The
simulated EEG signal consisted of a random signal similar
to real EEG. Feedback to a real EEG signal and the sim-
ulated EEG signal were similar in experience (Logemann
et al. 2010). During training, all children watched a movie
for 20 min. They were asked to sit as quiet as possible in a
comfortable arm chair in front of a 17–19 in. TFT com-
puter screen showing a part of the movie. EEG data were
obtained from the active electrode(s) placed on the scalp at
the location(s) of interest (Table 1). The reference was
linked ears or left ear if the active electrode was placed on
the middle of the scalp. All electrode impedances were
kept under 6 kX. Sampling rate was 256 Hz. EEG data
were ﬁltered (DC-120 Hz) and de-artefacted online (peak-
to-peak amplitude criterion of 120 lV). Positive feedback
was provided by both brightening the computer screen and
presenting an auditory tone when the production of SMR
(estimated from the ﬁltered and de-artefacted EEG signal)
remained above threshold, and/or theta and beta activity
(estimated from the ﬁltered and de-artefacted EEG signal)
remained below threshold. Reward threshold levels were
automatically adjusted based on the digitally ﬁltered real-
time EEG signal every 30 s so that the child was rewarded
about 80% of the time (i.e., received positive feedback).
Consequently, the amount of reward remained at about the
same level across sessions and across groups. During
training, children were instructed to try to self-regulate
their brain activity by receiving positive feedback based on
the real-time EEG signal. The children were trained over a
period of approximately 4 months with 2 sessions per
week, in total 30 sessions. The duration of each session was
45 min and included approximately 20 min of uninter-
rupted EEG-neurofeedback or placebo feedback training.
Training was conducted in an ‘active focusing state’ with
eyes open.
Outcome measures
In the present paper, the feasibility of the study design, the
safety results and the results regarding the effects of EEG-
neurofeedback training in comparison with placebo feed-
back training on ADHD symptom severity and global
improvement, rated by the investigator, are reported and
discussed. The results regarding the effects of EEG-
neurofeedback training on trained EEG oscillations are
provided in the electronic supplementary material.
Unfortunately, EEG data during training sessions were not
recorded. Cognitive data for the whole group and magnetic
resonance images (MRI) data acquired for a subgroup of
children are not reported here.
Feasibility measures
Feasibility was assessed by attendance of the study visits
and the training sessions. Additionally, in the ﬁnal inter-
view with the investigator after the treatment period, par-
ents and children were asked to indicate whether they
thought the child had received EEG-neurofeedback train-
ing or placebo feedback training.
Safety measures
To evaluate the safety, i.e., potential adverse effects of
EEG-neurofeedback or placebo-feedback training, parents
and children ﬁlled out the Pittsburgh side effects rating
scale (PSERS; Pelham et al. 2001; Sandler and Bodﬁsh
2008) before training and after 6, 10, 20, and 30 training
sessions. The PSERS measures the presence/absence and
severity (1 = mild, 2 = moderate, 3 = severe) of several
potential side effects (e.g., tics, skin picking, sleepiness,
headache, stomach ache, irritability, and appetite loss). For
the present study, three items were added to the original
PSERS: epileptic seizures, nausea, and feeling agitated.
Severity of adverse effects was calculated as the sum score
of all 15 items. For 1 child from the EEG-neurofeedback
group, adverse events after the training period were not
rated.
Sleep problems were assessed using 14 insomnia items
of the Dutch version of the Sleep Disorders Questionnaire
(SDQ; Sweere et al. 1998) before and after the treatment
period. Parents and children rated each item on a ﬁve-point
rating scale (0 = never, 1 = rarely, 2 = sometimes,
3 = usually, 4 = always) before and after the training
period. Total severity of sleep problems was deﬁned as the
sum score of all items. For 1 child from the EEG-neuro-
feedback group, sleep problems were not rated after the
training period.
Efﬁcacy measures
Efﬁcacy in the present pilot study was measured by the
total severity of inattention and hyperactive/impulsive
symptoms of ADHD according to the ADHD DSM-IV
scale (DuPaul et al. 1998), rated by the investigator in an
interview with the parents. Severity of the ADHD symp-
toms were rated (with a score from 0 to 3) before training,
after 6, 10, 20, 30 training sessions, and 6 months after the
end of the training period.
Global improvement was also included as a measure of
efﬁcacy and was assessed in the ﬁnal interview with the
parents using the Clinical Global Impressions-Improvement
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scaletoevaluateclinicaleffectsininterventionstudies.CGI-
Iconsistsofasingleitem7-point(1 = verymuchimproved,
2 = much improved, 3 = minimally improved, 4 = no
change, 5 = minimally worse, 6 = much worse, 7 = very
muchworse).CGI-Irespondersweredeﬁnedaschildrenthat
were rated as very much improved or much improved. The
CGI-I scale was missing for one child in the EEG-neuro-
feedback training group.
Electrophysiological recordings
Before and after training, EEG was recorded using
DeyMed TrueScan and an Electrocap with 19 electrodes
(according to the 10–20 electrode international system)
during a 10-min eyes open and 10-min eyes closed
resting-state condition. Data were referenced to a com-
mon reference placed between Fpz and Fz. The ground
electrode was placed at the forehead. EEG data were
ﬁltered online with a bandwidth of 0.1–102 Hz. Sam-
pling rate was 256 Hz. Electrode impedance was kept
below 10 kX.
Children were instructed to sit quietly for 20 min,
10 min with eyes open and 10 min with eyes closed.
Study procedure
After recruitment, screening and baseline assessments,
EEG-neurofeedback training or placebo feedback training
started for a period of approximately 4–5 months. After
6 training sessions, DSM-IV TR ADHD criteria were
evaluated in a telephone interview with the parents.
Additionally, parents ﬁlled out the PSERS to rate any
adverse events. After 10 and 20 training sessions, DSM-IV
TR ADHD criteria were again evaluated in a telephone
interview with the parents, and parents ﬁlled out the
PSERS. After the training period of 30 training sessions,
DSM-IV TR ADHD criteria were again evaluated in a
telephone interview with the parents, and parents ﬁlled out
the PSERS and SDQ. Furthermore, the EEG recordings,
neuropsychological test battery and MRI session were
repeated. In a ﬁnal interview by the investigator with the
parents, general clinical improvement (CGI-I) was asses-
sed. Additionally, the experiences of the training were
discussed and parents and children were asked to indicate
whether they thought the child had received EEG-neuro-
feedback training or placebo feedback training. Six months
after the end of the training period, DSM-IV TR ADHD
criteria were evaluated in a telephone interview with the
parents.
Since the main objective of the present paper was to
evaluate the feasibility and safety of using a placebo-con-
trolled design to test the efﬁcacy of EEG-neurofeedback
training in children with ADHD, the present paper focuses
on the feasibility and safety measures and some initial
results with respect to ADHD symptoms and global
improvement.
Statistical analysis
We conducted repeated-measures analysis of variance
(ANOVA) (two-tailed, signiﬁcance level is set at 5%) with
TIME as within-subjects factor and GROUP (EEG-neuro-
feedback vs. placebo neurofeedback) as between-subjects
factor separately for the severity of adverse events, severity
of sleep problems (SDQ), severity of inattention symptoms,
and severity of hyperactive/impulsive symptoms. For
severity of adverse events and the severity of inattention
symptoms and hyperactive/impulsive symptoms, within-
subject factor TIME had 5 levels (i.e., before and after 6,
10, 20 and 30 training sessions). For the severity of sleep
problems (SDQ), TIME had 2 levels (before and after
training).
Follow-up assessment of the severity of ADHD symp-
toms, rated by the investigator, was compared with the
severity of ADHD symptoms immediately after the train-
ing period using repeated-measures ANCOVAs with
between-subject factor GROUP (EEG-neurofeedback vs.
placebo neurofeedback), within-subject factor TIME (post-
training, follow-up) using the baseline (pre-training) mea-
sure as a covariate.
Results
At baseline, all children were rated as moderately ill
(n = 11) or markedly ill (n = 3) by the psychiatrist using
the CGI-S. Baseline assessments of ADHD severity, based
on the ADHD DSM-IV scale, indicated enough room for
improvement for all children (Table 2). Five of 8 children
in the EEG-neurofeedback group and 4 of 6 children in the
placebo feedback group were medicated with psychostim-
ulants (methylphenidate or dextroamphetamine; for details,
see Table 2). None of the children changed type or dose of
medication during participation of the study.
Feasibility
From the 14 children with ADHD who started the EEG-
neurofeedback or placebo feedback training, all children
completed the study. Additionally, participating children
and parents attended all study visits and all training ses-
sions. Regarding the expectancy of group assignment, 2 of
8 children and their parent(s) in the active EEG-neuro-
feedback group and 2 of 6 children and their parent(s) in
the placebo feedback group thought they received active
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feedback group thought he received active EEG-neuro-
feedback, whereas his parents thought he received placebo
feedback. The other children and their parent(s) [6 of 8
(75%) in the active EEG-neurofeedback group; 3 of 6
(50%) in the placebo feedback group] thought the child
received placebo feedback training. So, parent’s and
child’s prediction of which training group the child was
assigned to was at chance level.
Safety
The average number of ‘adverse events’ before the start of
the EEG-neurofeedback training was 2.5 ± 2.4 (with a
total severity of 3.9 ± 3.8). ‘‘Skin picking’’ and ‘‘irritable’’
were the most often reported adverse events. For all chil-
dren, the severity of adverse events did not increase or
decrease over time during the training period (Table 3).
Total severity of sleep problems did also not signiﬁcantly
increase or decrease over time (Table 3).
Efﬁcacy
Table 3 presents behavioral data before and after training,
separately for the EEG-neurofeedback and placebo feed-
back training group. As shown in Figs. 1a and 1b, the total
severity of DSM-IV symptoms of inattention and hyper-
activity/impulsivity rated by the investigator decreased
signiﬁcantly over time (main effect of time: F(4,48) =
22.07, p\.001 and F(4,48) = 8.09, p\.001 for inattention
and hyperactivity/impulsiveness, respectively) but the
improvement in ADHD symptoms were present in both
groups (i.e., there was no signiﬁcant time 9 group inter-
action effects).
CGI-I results showed that only one child (in the EEG-
neurofeedback training group) was rated as a responder
(i.e., rated as ‘‘much improved’’). Two children in the
EEG-neurofeedback group and 2 children in the placebo
feedback group were rated as ‘‘minimal improved’’. Four
of 8 children in the EEG-neurofeedback training group and
4 of 6 children in the placebo feedback training group did
not show any clinical global improvements. None of the
children deteriorated.
Regarding the follow-up assessment of total severity of
DSM-IV symptoms of inattention and hyperactivity/
impulsivity, repeated measures ANCOVA did not yield
signiﬁcant main effects of group or time, or a signiﬁcant
group 9 time interaction effect. These results indicate no
differences between ADHD symptoms directly after the
training period and ADHD symptoms 6 months after the
end of the training period.
Table 2 Dosage and type of
medication, and ADHD severity
at baseline (based on the ADHD
DSM-IV scale) for each child
Hyp/Imp Hyperactivity/
impulsivity symptoms, NF
EEG-neurofeedback, MPH
methylphenidate, d-amf
dextroamphetamine
Child Group Medication ADHD severity—baseline
Inattention Hyp/Imp
999 NF MPH (5 mg) ? concerta (54 mg) 17 11
997 NF MPH (15–10–5 mg) 5 20
995 NF MPH (10 mg) ? concerta (36 mg) 16 18
992 NF Concerta (36 mg) ? melatonine (3 mg) 21 23
989 NF – 23 17
987 NF – 26 17
984 NF – 26 1
983 NF MPH (10–10–5 mg) ? melatonine (2.5 mg) 18 15
998 Placebo MPH (10–10 mg) 21 26
996 Placebo – 12 14
994 Placebo MPH (10–10 mg) ? melatonine (3 mg) 24 10
993 Placebo MPH (10 mg) ? concerta (18 mg) 17 21
990 Placebo d-amf (7.5–7.5 mg) ? melatonine (3 mg) 23 16
986 Placebo – 18 20
Table 3 Behavioral data before training and after training for the
EEG-neurofeedback group and placebo-feedback group
EEG-neurofeedback Placebo-feedback
Pre Post Pre Post
Severity sleep problems 13.7 (7.3) 9.3 (4.7) 9.5 (8.0) 8.5 (7.1)
Severity adverse events 3.3 (3.8) 2.3 (1.7) 3.8 (3.8) 3.0 (3.9)
Severity Inatt—parent 19.0 (6.8) 13.4 (7.8) 19.2 (4.4) 12.5 (2.3)
Severity Hyp/Imp—parent 15.3 (6.7) 10.3 (6.0) 17.8 (5.7) 14.7 (6.2)
CGI-I 3.4 (0.8) 3.7 (0.5)
Reduced scores reﬂect improvement for all scales. Clinical Global
Impression (CGI) score ranged from 1 (very much improved) to 7 (very
much worse). Standard deviations of the mean are given in parentheses
Inatt DSM-IV inattentive symptoms, Hyp/Imp DSM-IV hyperactive/
impulsive symptoms, CGI-I Clinical Global Impression—Improvement
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Consistent evidence for improvements in ADHD symptoms
after EEG-neurofeedback training in children with ADHD
have been provided by several studies (Arns et al. 2009;
Gevensleben etal.2009;Heinrichetal.2007).However,the
majorityofthesestudies havemethodologicallimitations.A
rigorous double-blind placebo-controlled trial has not yet
been publishedinapeer-reviewedinternationaljournal.The
mainreasonsforthelackofsuchacomplementarydesignare
(1)theethicalissueofwithholdingevidence-basedtreatment
and (2) the doubts about the feasibility of placebo-neuro-
feedback (Kotchoubey et al. 2001; La Vaque and Rossiter
2001). The main objective of the present pilot study was to
testthefeasibilityandsafetyofusingarigorousdouble-blind
placebofeedback-controlleddesigninstudyingtheeffectsof
individualized neurofeedback training in children with
ADHD. To overcome the problem of withholding evidence-
based treatment, children were allowed to use medication,
but were not allowed to switch drug or dosage.
To account for electrophysiological heterogeneity,
individualized neurofeedback protocols were determined
for the participating children based on their baseline EEG
activity. As presented in Table 1, most children received
theta suppression/SMR enhancement training, which is one
of the most often used neurofeedback training protocols
(Monastra et al. 2005).
In this pilot study, all included children completed the
30 training sessions and attended all study visits. With
respect to safety, neither EEG-neurofeedback training nor
placebo-feedback training evoked signiﬁcant adverse
events or sleep problems, indicating that EEG-neurofeed-
back and placebo feedback may not have serious side
effects. Further, 3 of 6 children from the placebo-feedback
group thought they received active EEG-neurofeedback
training. Providing placebo neurofeedback training as a
control condition thus appears to be a ‘feasible’ approach.
Indeed, placebo feedback has previously been applied in
other populations (learning disabled children, Fernandez
et al. 2007; elderly, Angelakis et al. 2007; healthy volun-
teers, Egner et al. 2002; Logemann et al. 2010).
Blinded analysis of this ongoing EEG-neurofeedback
study demonstrated clinical improvement over time, as
reﬂected in reduced ADHD DSM-IV symptoms rated by
the investigator, but did not reveal signiﬁcant differences
between the EEG-neurofeedback training group and pla-
cebo feedback group. Thus, individualized EEG-neuro-
feedback training did not outperform placebo feedback
training in improvement of clinical symptoms in ADHD
children. Of course, the power of this interim sample is
limited, as we had projected to need a sample of 120
subjects in total. However, not even a trend was found for
any group 9 time interaction effects (F\1). The present
ﬁndings suggest that the behavioral improvements
observed in this study after individualized EEG-neuro-
feedback training may not be caused by the ability to self-
regulate brain activity, but rather by unspeciﬁc effects such
as invested time and attention, therapist interaction,
expectancy, or just by passed time. This ﬁnding may raise
doubt on the positive results of previous studies that did not
completely control for unspeciﬁc factors. However, several
important issues have to be discussed. First, the EEG-
neurofeedback training as provided in the present study
was adjusted to each child (i.e., individualized EEG-
neurofeedback), whereas previous studies all provided
standardized neurofeedback training. It may be speculated
thatindividualizedEEG-neurofeedbackasmostlyappliedin
practice with the aim to normalize ‘deviant’ brain activity is
not effective, whereas standardized EEG-neurofeedback
training with the aim to self-control brain activity is effec-
tive. The deviation from the normative EEG database may
just indicate electrophysiological heterogeneity that is
normal or even adaptive rather than pathological. Second,
Fig. 1 Total severity of ADHD Inattentive symptoms (a) and ADHD
hyperactive/impulsive symptoms (b) before training and after 6, 10,
20, 30 sessions of EEG-neurofeedback, and at follow-up (FU;
6 months) for the EEG-neurofeedback and placebo-feedback group
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neurofeedback therapist did not know to which group the
child was assigned, automatic reward threshold adjustments
were used to provide EEG-neurofeedback training. How-
ever, EEG-neurofeedback training based on automatic
adjusted reward thresholds might not work as effective as
EEG-neurofeedback training based on manual adjusted
reward thresholds (Logemann et al. 2010). In line with this
suggestion, the majority of children and their parents from
the active EEG-neurofeedback training group (6 of 8)
thought they received placebo feedback training. A third
limitation of this study is the lack of actively practicing
mental strategies to self-regulate brain activity (e.g.,
Gevensleben et al. 2009). In other words, EEG-neurofeed-
back might need explicit learning rather than implicit
learning. Finally, as indicated by Monastra et al. (2005), it
may be important to control for variations in parenting style
that may mediate treatment response.
Given these limitations and in the ﬁrst place the small
sample size in this study, we believe it is preliminary to
conclude that individualized EEG-neurofeedback training
is not effective in improving ADHD symptoms. We may
conclude from the present ﬁndings that it is feasible to
conduct a rigorous placebo-controlled trial to investigate
the efﬁcacy of EEG-neurofeedback training in children
with ADHD placebo-feedback, arguing against earlier
statements that placebo feedback is impossible (Kotchou-
bey et al. 2001). However, a double-blind design may not
be feasible since using automatic adjusted reward thresh-
olds may not work as effective as manually adjusted
reward thresholds.
Based on these results we have made two changes in our
ongoing EEG-neurofeedback study. First, we will provide
EEG-neurofeedback training in which the trainer adjusts
manually the feedback parameters with the consequence
that the trainer will not be blind to group assignment.
Children, their parents, and all other people involved in the
study will be still blind to group assignment. Second, we
will assist children in developing and practicing active
learning strategies to self-regulate brain activity (e.g.,
focusing one’s attention) and promote the children to
implement the acquired strategies in daily-life situations,
aimed at optimizing the therapeutic effects of EEG-neu-
rofeedback training (see Gevensleben et al. 2009).
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